{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T17:11:28Z","timestamp":1783357888392,"version":"3.54.6"},"reference-count":6,"publisher":"American Medical Association (AMA)","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Oncol"],"published-print":{"date-parts":[[2018,12,1]]},"DOI":"10.1001\/jamaoncol.2018.5457","type":"journal-article","created":{"date-parts":[[2018,11,26]],"date-time":"2018-11-26T22:33:53Z","timestamp":1543271633000},"page":"1781","source":"Crossref","is-referenced-by-count":37,"title":["Remission and Progression-Free Survival in Patients With Newly Diagnosed Multiple Myeloma Treated With Carfilzomib, Lenalidomide, and Dexamethasone"],"prefix":"10.1001","volume":"4","author":[{"given":"Dickran","family":"Kazandjian","sequence":"first","affiliation":[{"name":"Myeloma Program, Lymphoid Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neha","family":"Korde","sequence":"additional","affiliation":[{"name":"Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York City"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sham","family":"Mailankody","sequence":"additional","affiliation":[{"name":"Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York City"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Hill","sequence":"additional","affiliation":[{"name":"Myeloma Program, Lymphoid Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William D.","family":"Figg","sequence":"additional","affiliation":[{"name":"Department of Pharmacokinetics, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Roschewski","sequence":"additional","affiliation":[{"name":"Myeloma Program, Lymphoid Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ola","family":"Landgren","sequence":"additional","affiliation":[{"name":"Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York City"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"10068","key":"cld180035r1","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/S0140-6736(16)31594-X","article-title":"Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial.","volume":"389","author":"Durie","year":"2017","journal-title":"Lancet"},{"issue":"6","key":"cld180035r2","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1053\/j.seminoncol.2016.10.008","article-title":"A look backward and forward in the regulatory and treatment history of multiple myeloma: approval of novel-novel agents, new drug development, and longer patient survival.","volume":"43","author":"Kazandjian","year":"2016","journal-title":"Semin Oncol"},{"issue":"8","key":"cld180035r3","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1200\/JCO.2017.76.5032","article-title":"Improvement in overall survival with carfilzomib, lenalidomide, and dexamethasone in patients with relapsed or refractory multiple myeloma.","volume":"36","author":"Siegel","year":"2018","journal-title":"J Clin Oncol"},{"issue":"2","key":"cld180035r4","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1056\/NEJMoa1411321","article-title":"Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma.","volume":"372","author":"Stewart","year":"2015","journal-title":"N Engl J Med"},{"issue":"6","key":"cld180035r5","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1001\/jamaoncol.2015.2010","article-title":"Treatment with carfilzomib-lenalidomide-dexamethasone with lenalidomide extension in patients with smoldering or newly diagnosed multiple myeloma.","volume":"1","author":"Korde","year":"2015","journal-title":"JAMA Oncol"},{"issue":"12","key":"cld180035r6","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1038\/bmt.2016.222","article-title":"Role of MRD status in relation to clinical outcomes in newly diagnosed multiple myeloma patients: a meta-analysis.","volume":"51","author":"Landgren","year":"2016","journal-title":"Bone Marrow Transplant"}],"container-title":["JAMA Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/fullarticle\/2716069","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,12,13]],"date-time":"2018-12-13T16:03:10Z","timestamp":1544716990000},"score":1,"resource":{"primary":{"URL":"http:\/\/oncology.jamanetwork.com\/article.aspx?doi=10.1001\/jamaoncol.2018.5457"}},"subtitle":["Five-Year Follow-up of a Phase 2 Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2018,12,1]]},"references-count":6,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2018,12,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaoncol.2018.5457","relation":{},"ISSN":["2374-2437"],"issn-type":[{"value":"2374-2437","type":"print"}],"subject":[],"published":{"date-parts":[[2018,12,1]]}}}